Artiva Biotherapeutics, Inc. ARTV Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -67.9%-11.3pp | -56.5%-8.6pp | -48%— | —— | —— | |
| Return on assets | -58.6%-9.3pp | -49.3%-7.0pp | -42.3%+19.0pp | -61.3%— | —— | |
| Return on invested capital | -80.5%-9.9pp | -70.6%-7.9pp | -62.7%— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 8.2×-0.5× | 8.6×-3.0× | 11.6×-2.2× | 13.8×-0.1× | 13.9×-1.5× | |
| Quick ratio | 8.2×-0.5× | 8.6×-3.0× | 11.6×-2.2× | 13.8×-0.1× | 13.9×-1.5× | |
| Cash ratio | 2×-0.1× | 2.1×-0.3× | 2.3×-0.4× | 2.7×+0.2× | 2.5×-0.8× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $3.56-20.9% | $4.50-14.8% | $5.28-13.7% | $6.11-11.8% | $6.93-58.2% | |
| Valuation | ||||||
| Market capitalization | $429.03M+1,015% | $105.3M+50.2% | $70.1M+78.7% | $39.22M-46.3% | $73.09M-70.1% | |
| Enterprise value | $417.88M+1,832% | $89.08M+59.6% | $55.82M+137% | $23.52M-58.2% | $56.22M-74.3% | |
| Price / book | 4.9×+4.7× | 1×+0.4× | 0.5×+0.3× | 0.3×-0.2× | 0.4×-0.9× | |
| Free cash flow yield | -18.7%+140pp | -75.3%+37.2pp | -112.6%+68.0pp | -180.5%-97.2pp | -83.4%-60.6pp | |
| Earnings yield | -20.3%+166pp | -79.6%+33.3pp | -113%+78.6pp | -191.5%-93.4pp | -98.1%-71.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Artiva Biotherapeutics, Inc.'s ratios come from?
- Every ratio is computed from Artiva Biotherapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.